Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China; The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China.
J Ethnopharmacol. 2023 Feb 10;302(Pt A):115878. doi: 10.1016/j.jep.2022.115878. Epub 2022 Oct 29.
Qian Yang Yu Yin granules (QYYYG) have a long history in the treatment of hypertensive renal damage (HRD) in China. Clinical studies have found that QYYYG stabilizes blood pressure and prevents early renal damage. However, the exact mechanism is not entirely clear.
To evaluate the therapeutic effect and further explore the therapeutic mechanism of QYYYG against HRD.
The efficacy of QYYYG in treating HRD was assessed in spontaneous hypertension rats (SHR). Renal autophagy and the TRPC6-CaMKKβ-AMPK pathway in rats were evaluated. The regulatory role of QYYYG in angiotensin II (Ang II) induced abnormal autophagy in rat podocytes was determined by detecting autophagy-related proteins, intracellular Ca content, and the TRPC6-CaMKKβ-AMPK-mTOR pathway expressions. Finally, we established a stable rat podocyte cell line overexpressing TRPC6 and used the cells to verify the regulatory effects of QYYYG.
QYYYG alleviated HRD and reversed the abnormal expression of autophagy-related genes in the SHR. In vitro, QYYYG protected against Ang II-induced podocyte damage. Furthermore, treatment of podocytes with QYYYG reversed Ang II-induced autophagy and inhibited Ang II-stimulated TRPC6 activation, Ca influx and activation CaMKKβ-AMPK pathway. Overexpression of TRPC6 resulted in pronounced activation of CaMKKβ, AMPK, and autophagy induction in rat podocytes, which were significantly attenuated by QYYYG.
The present study suggested that QYYYG may exert its HRD protective effects in part by regulating the abnormal autophagy of podocytes through the TRPC6-CaMKKβ-AMPK-mTOR pathway.
千阳育阴颗粒(QYYYG)在中国治疗高血压肾损害(HRD)方面有着悠久的历史。临床研究发现,QYYYG 能稳定血压,预防早期肾损害。然而,确切的机制尚不完全清楚。
评估 QYYYG 治疗 HRD 的疗效,并进一步探讨其治疗机制。
在自发性高血压大鼠(SHR)中评估 QYYYG 治疗 HRD 的疗效。评估大鼠肾自噬和 TRPC6-CaMKKβ-AMPK 通路。通过检测自噬相关蛋白、细胞内 Ca 含量和 TRPC6-CaMKKβ-AMPK-mTOR 通路表达,确定 QYYYG 在血管紧张素 II(Ang II)诱导的大鼠足细胞异常自噬中的调节作用。最后,我们建立了稳定过表达 TRPC6 的大鼠足细胞细胞系,并利用该细胞系验证了 QYYYG 的调节作用。
QYYYG 缓解了 HRD 并逆转了 SHR 中异常的自噬相关基因表达。在体外,QYYYG 可防止 Ang II 诱导的足细胞损伤。此外,用 QYYYG 处理足细胞可逆转 Ang II 诱导的自噬,并抑制 Ang II 刺激的 TRPC6 激活、Ca 内流和激活 CaMKKβ-AMPK 通路。TRPC6 的过表达导致大鼠足细胞中 CaMKKβ、AMPK 和自噬的明显激活,而 QYYYG 可显著减弱这种激活。
本研究表明,QYYYG 可能通过调节足细胞的异常自噬,通过 TRPC6-CaMKKβ-AMPK-mTOR 通路发挥其对 HRD 的保护作用。